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Primary congenital glaucoma (PCG, OMIM 231300) is 
an important cause of glaucoma blindness in children and 
results from a developmental defect of the aqueous outflow 
system. It is characterized by increased intraocular pressure 
(IOP), buphthalmos, corneal clouding, and Haab’s striae, 
and it generally manifests in the neonatal or early infantile 
period [1]. The level of incidence varies across different 
ethnic groups. A high incidence has been found among some 
populations (Slovakian Gypsies 1/1250 [2], Saudi Arabian 
1/2500 [3]), but it is usually lower in Western countries 
(1/22,000–1/23,000) [2,4]. In Australia, PCG has an incidence 
of 1/30,000 births [5].
CYP1B1 (GLC3A, OMIM 601771) on chromosome 2p21 
was the first gene discovered to cause PCG [6]. Pathogenic 
variants in CYP1B1 have been identified among different 
populations [7-13], and they have been reported to occur in as 
few as 15% (in an American cohort) [12] and as high as 92% 
(in a Saudi Arabian cohort) [3] of PCG patients. In Australia, 
CYP1B1 variants occur in 22% of PCG cases [14]. Four other 
PCG loci have been described (GLC3B-E), and LTBP2 has 
been identified on chromosome 14q24 (GLC3C, OMIM 
602091) [15]. However, a more recent study suggested that 
LTBP2 variants might be responsible for primary congenital 
megalocornea with secondary glaucoma [16].
CYP1B1 is a member of the cytochrome P450 super-
family and is composed of three exons, of which only the last 
two are coding. The protein is responsible for the metabolism 
of a wide range of diverse substrates, both endogenous and 
exogenous [17]. Functional studies have demonstrated that 
CYP1B1 pathogenic variants reduce the enzymatic activity or 
stability of the enzyme [18,19]. The mechanism by which they 
cause glaucoma is not fully understood, but it is hypothesized 
that the expressions of genes important to the development 
of the eye may be altered by the level of key regulatory mole-
cules or the presence of normally eliminated metabolites [17].
CYP1B1 pathogenic variants are inherited in an auto-
somal recessive manner. However, individuals with PCG 
harboring only one pathogenic variant in CYP1B1 have been 
reported [7-9,13,14]. These patients might have a second 
variant in the promoter, a non-coding region, or a deletion of 
a part of or the entire gene on their other allele, explaining 
their phenotype. No study has evaluated the prevalence of 
CYP1B1 copy number variation (CNV) among PCG cases. 
In this report, we investigated whether CYP1B1 gene CNV 
accounts for PCG cases heterozygous for CYP1B1 muta-
tions or with no pathogenic sequence variant, as identified 
through gene sequencing, and we explored the diagnostic use 
of testing for CYP1B1 CNV.
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Purpose: To evaluate the prevalence and the diagnostic utility of testing for CYP1B1 copy number variation (CNV) in 
primary congenital glaucoma (PCG) cases unexplained by CYP1B1 point mutations in The Australian and New Zealand 
Registry of Advanced Glaucoma.
Methods: In total, 50 PCG cases either heterozygous for disease-causing variants or with no CYP1B1 sequence variants 
were included in the study. CYP1B1 CNV was analyzed by Multiplex Ligation-dependent Probe Amplification (MLPA).
Results: No deletions or duplications were found in any of the cases.
Conclusion: This is the first study to report on CYP1B1 CNV in PCG cases. Our findings show that this mechanism is 
not a major contributor to the phenotype and is of limited diagnostic utility.
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METHODS
Recruitment of participants: Ethics approval was obtained 
from the Southern Adelaide Clinical Human Research Ethics 
Committee. The study was conducted in accordance with the 
revised Declaration of Helsinki and following the National 
Health and Medical Research Council statement of ethical 
conduct in research involving humans.
Individuals with PCG were recruited through the Austra-
lian and New Zealand Registry of Advanced Glaucoma by 
referral from their eye practitioner [20]. Informed written 
consent and a blood sample for DNA extraction purposes 
were obtained. Clinical information was collected by the 
patient’s usual clinical ophthalmologist. The diagnosis of 
PCG was based on combinations of corneal enlargement 
and buphthalmos, loss of corneal transparency, photophobia, 
raised IOP, or optic disc cupping.
Genetic testing: All PCG cases had bidirectional sequencing 
of the two CYP1B1 coding exons and the respective intron–
exon boundaries. Cases with two confirmed pathogenic 
sequence variants identified were excluded from the current 
analysis. Our cohort consisted of PCG patients with only 
one pathogenic sequence variant, with sequence variants 
of unknown clinical significance, or with no pathogenic 
sequence variants identified in the CYP1B1 gene (n = 50).
CYP1B1 was analyzed for copy number abnormalities by 
Multiplex Ligation-dependent Probe Amplification (MLPA) 
using the SALSA MLPA P128 Cytochrome P450 probemix 
(MRC Holland, Amsterdam, The Netherlands) according to 
the manufacturer’s instructions. MLPA allows for the detec-
tion of small copy number changes to the DNA sequence of 
a gene [21]. The probes consisted of two oligonucleotides 
complementary to adjacent sequences of the target DNA. 
The two probe sequences were joined by DNA ligase. Perfect 
homology between the two probes with the target at this junc-
tion is required for this step. The probes were then denatured 
from the template and amplified in a multiplex PCR reaction 
with the use of a single primer pair. Each probe generated 
an amplification product of a unique length, allowing for the 
separation of products by capillary electrophoresis. An indi-
rect measurement of the copy number present in the original 
DNA specimen was determined from the relative amplitude of 
each amplicon product detected using the ABI 3130xl Genetic 
Analyzer (Life Technologies, CA), as well as analyzed using 
the Peak Scanner Software v1.0 (Life Technologies).
The P128 Cytochrome P450 probemix contained internal 
controls. The kit included probes targeting copy number 
changes of 14 Cytochrome P450 and Glutathione S-trans-
ferase genes. In addition, 12 reference probes allowed for the 
detection of several different autosomal chromosomal loca-
tions and probes to the X and Y chromosome were included.
RESULTS
We studied 50 individuals with PCG, with 20 being female 
(40%) and 30 being male (60%). The majority were Cauca-
sian (78%), while the rest were of African (8%), Asian (6%), 
Melanesian (2%), and Middle Eastern (6%) backgrounds. 
Most cases were diagnosed before the age of 3 years (92%). A 
family history of PCG was present in four patients; three had 
affected siblings and one had an affected parent. The mean 
highest IOP was 29.5±9.3 mmHg and the mean cup-to-disc 
ratio was 0.6±0.3.
Prior to this study, all cases had been directly sequenced 
for CYP1B1 variants. Three of the included cases were 
heterozygous for previously reported variants (R444Q, 
P513_K514del, and E229K [14,22]). An MLPA analysis was 
successful in all 50 patients. Internal controls detected several 
copy number changes in some patients in regions that are 
known to differ in copy number within the normal population 
(e.g., GSTM1 and GSTT1 genes). Moreover, we were able to 
correctly identify the sex of the individuals tested with probes 
to both the X and Y chromosomes. No CYP1B1 CNV of part 
of or the entire gene was detected in any cases.
Table 1. CYP1B1 deleTions in primary congeniTal glaucoma previously reporTed (reference genome grch37). 
Location (Chr2) Size Deletion Genotype Ethnicity Family history Ref
Intragenic Intron 2 - exon 3 Partial Homozygous Turkish
Segregated in 3 affected 
siblings  [5,23]
38,222,086 
– 38,368,231 146 kb Whole gene Homozygous Cypriot Negative  [25]
38,191,823 
– 38,385,253 193 kb Whole gene Homozygous Caucasian
Segregated in 2 affected 
siblings  [26]
38,187,289 
–38,349,505 162 kb Whole gene
Compound hetero-
zygous (T404fs*30) Spanish Negative  [24]
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DISCUSSION
CYP1B1 is the only known gene to cause PCG in our popula-
tion to date. Its prevalence among PCG cases varies across 
different populations, but overall, it accounts for approxi-
mately one in five cases in Caucasians [9,12-14]. Cases hetero-
zygous for known pathogenic variants have been frequently 
reported [7-9,11,13,14]. In these situations, the other allele 
could display a variant in the promoter, in a non-coding 
region, or a deletion of part of or the entire gene. Whole gene 
deletions or duplications have been identified to be causative 
in other glaucoma-associated genes, such as PITX2, FOXC1, 
or TBK1 [23,24]. Moreover, a few isolated cases of partial or 
whole gene CYP1B1 deletions have been previously reported 
(Table 1) [6, 25–28]. In this study, we screened 50 PCG cases, 
in which CYP1B1 sequencing results did not fully explain 
the phenotype, for CYP1B1 CNV. An MLPA analysis did not 
detect any intragenic deletions or duplications in this cohort.
The intragenic deletion reported by Stoilov et al. was 
identified through the sequencing of the coding exons [6,25]. 
Other CYP1B1 whole gene deletions previously reported 
were identified because of suspicious sequencing results: two 
studies reported a homozygous whole-gene deletion following 
repeated failures to amplify the CYP1B1 coding exons through 
sequencing [27,28]. A third study found an apparently homo-
zygous pathogenic variant in a patient that was present in the 
heterozygous state in the mother, but not in the father. After 
excluding non-paternity and maternal disomy, a gene dosage 
assessment revealed a heterozygous deletion on the other 
allele in the patient [26]. Although some deletions would be 
suspected by gene sequencing, others would still be missed. 
The four cases of CYP1B1 CNV previously reported were all 
detected by chance through direct sequencing. This is the 
first study to assess directly the prevalence of CYP1B1 CNV 
and to explore whether such a test would be of diagnostic 
use to complement CYP1B1 gene sequencing. Although we 
cannot deny that this mechanism does play a role in rare PCG, 
the prevalence of such mutations in Caucasian PCG cases is 
expected to be less than 1%. As the probes used cover exons 1 
and 3 only, we cannot completely exclude the possibility of an 
intragenic exon 2 CNV. However, the three whole gene dele-
tions and the intragenic deletion previously published would 
have been detected with the probes used. Further, as we did 
not detect any CNV in this gene, the diagnostic potential of 
such a test is not high.
In conclusion, we did not identify any CYP1B1 CNV 
among 50 PCG cases recruited through the Australian and 
New Zealand Registry of Advanced Glaucoma. To the best of 
our knowledge, this is the first study to report MLPA results 
for the CYP1B1 gene in PCG cases and to assess its clinical 
utility. CYP1B1 CNV is not a major contributor to PCG in our 
cohort of cases CYP1B1-negative or heterozygous through 
sequencing. It would be interesting to assess the prevalence 
of CYP1B1 CNV in other populations, especially in those 
where CYP1B1 mutations are more prevalent. This finding 
does not exclude this mechanism occurring rarely, but it 
means that research efforts should be focused on identifying 
further causative genes that when mutated cause PCG, and 
that testing for CYP1B1 CNV as a diagnostic procedure in 
PCG is likely to have a low yield.
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